Recombinant Human GM-CSF Protein, Biotinylated
Beta LifeScience
SKU/CAT #: BLPSN-2283
Recombinant Human GM-CSF Protein, Biotinylated
Beta LifeScience
SKU/CAT #: BLPSN-2283
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Tag | N/A |
Host Species | Human, Biotinylated |
Accession | NP_000749.2 |
Synonym | CSF2, GM-CSF, GMCSF |
Background | Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. The active form of the protein is found extracellularly as a homodimer, and the encoding gene is localized to a related gene cluster at chromosome region 5q31 which is known to be associated with 5q-syndrome and acute myelogenous leukemia. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients. GM-CSF deficiency in pregnancy adversely impacts fetal and placental development, as well as progeny viability and growth after birth, highlighting this cytokine as a central maternal determinant of pregnancy outcome with clinical relevance in human fertility.Immune CheckpointImmunotherapyCancer ImmunotherapyTargeted Therapy |
Description | A DNA sequence encoding the human CSF2 (NP_000749.2) (Met1-Glu144) was expressed. The purified protein was biotinylated in vitro. |
Source | HEK293 |
Predicted N Terminal | Ala 18 |
AA Sequence | Met1-Glu144 |
Molecular Weight | The recombinant human CSF2 consists of 127 a.a. and predicts a molecular mass of 14.5 kDa. |
Purity | >85% as determined by SDS-PAGE. |
Endotoxin | < 1.0 EU per μg protein as determined by the LAL method. |
Bioactivity | Please contact us for detailed information |
Formulation | Lyophilized from sterile Sterile PBS.. |
Stability | The recombinant proteins are stable for up to 1 year from date of receipt at -70°C. |
Usage | For Research Use Only |
Storage | Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |